Forbion News and Activities

View the org chart displaying its 53 main executives

Most searched biographies at Forbion

• Sander Slootweg, Managing Partner
• Geert-Jan Mulder, Managing Partner
• Martien van Osch, Managing Partner and Chief Financial Officer

Popular executive movements at Forbion

• Gökben Koca has joined the company as Venture Partner  (posted on June 19 2026).
• Jon Edwards, who was Partner, is promoted to General Partner  (posted on June 19 2026).
• Joost de Rijk has joined the company as Investor Relations Director  (posted on June 19 2026).

Click here to view some more movements at Forbion

Create your alert
to follow the executive moves at Forbion.

Forbion has 1,657 competitors including BlackRock (United States (USA)), KKR (United States (USA)) and Griffin Gaming Partners (United States (USA)).

Popular M&A news in Fund

• Sixth Street has announced the acquisition of Monument Re  (posted on June 29 2026).
• Arcline has announced the acquisition of AstroNova  (posted on June 24 2026).
• The project of Yellow Wood Partners acquiring Edgewell Personal Care has been abandoned  (posted on June 24 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director at General Catalyst Partners

Learn more about the Fund industry

Press releases by Forbion

• Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer | Forbion
• Biotech's Coming of Age - Nature Biotech | Forbion
• Human microglial transitions at the Aβ–tau inflection point associate with divergent pathways to dementia and resilience | Forbion
• Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner | Forbion
• AIRNA Appoints Todd Bazemore as President & CEO | Forbion
• Complement Therapeutics Announces Completion of Cohort 1 Dosing and Favourable Independent Data Monitoring Committee Recommendation in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD | Forbion
• Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research | Forbion
• Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial | Forbion
• Dyne Therapeutics Announces Initiation of Phase 3 Trial | Forbion
• Azafaros strengthens leadership team with appointment of Amy Sullivan as Chief Financial Officer | Forbion
• View more press releases Close

Social media about Forbion

• Forbion on Wikipedia, Google News & Yahoo Finance
• Forbion on LinkedIn, X (Twitter) & YouTube